Zenon Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Zenon Biotech is pioneering a novel therapeutic approach by targeting mechano-sensors—cellular receptors that respond to pathological tissue stiffness—in fibrotic diseases and cancer. Founded by Harvard scientist-entrepreneur David Lagares, the company is built on world-leading expertise in mechanobiology and is in the preclinical stage of developing its drug pipeline. Its platform aims to address significant unmet needs in diseases like IPF and Crohn's, where current anti-inflammatory or anti-fibrotic therapies are inadequate, positioning Zenon at the forefront of a new drug class termed 'mechano-therapeutics'.

OncologyImmunologyFibrotic Diseases

Technology Platform

A proprietary 'Mechano-Therapeutics' platform focused on discovering and developing drugs that target cellular mechano-sensors. These sensors are upregulated in pathological cells in response to increased tissue stiffness, a key driver in inflammation, aging, fibrosis, and cancer. The platform leverages deep expertise in fibroblast mechanobiology to identify novel disease intervention points.

Opportunities

Zenon operates in large, underserved markets like idiopathic pulmonary fibrosis and fibrotic Crohn's disease, where current therapies do not halt or reverse disease progression.

Its first-in-class mechano-therapeutics platform could establish a new drug modality, offering a foundational competitive advantage and creating significant partnership or acquisition interest from larger pharma companies seeking innovation in fibrosis and immuno-oncology.

Risk Factors

The core scientific risk is high, as the mechano-sensor target class is novel and unproven clinically, leading to potential efficacy or safety failures.

As a private, preclinical company, Zenon faces significant financing risk and must successfully raise capital in a competitive environment to advance its pipeline.

It also operates in a crowded therapeutic space with well-funded competitors exploring fibrosis and senescence.

Competitive Landscape

Zenon's direct competition is limited as a pioneer in mechano-therapeutics, but it faces indirect competition from numerous biopharma companies developing anti-fibrotics, senolytics, and anti-inflammatory therapies for the same indications. Its success depends on validating a new biological paradigm distinct from the cytokine-focused approaches of most competitors. Companies like Pliant Therapeutics and Promedior (acquired by Bristol Myers Squibb) represent advanced competitors in fibrosis, though with different targets.

More companies in United States →